Braveheart Investment Group announced the appointment of Dr Susan (Sue) Anne Hagan as a Non-Executive Director to the Board. She will also be a member of the Remuneration, Audit and Compliance committees. Dr Sue Hagan brings a wide range of experience in research, development and commercialization of medical devices, in-vitro diagnostic (IVD) medical devices, therapeutics and related healthcare products. Currently, Sue is working on a COVID-19 in-vitro diagnostic point of care device, assisting with regulatory and clinical issues. Previously, with start-up biotech Astrimmune Ltd, she was instrumental in obtaining grants leading to collaborations with the University of Sheffield and the University of Cambridge for the development of a non-invasive bladder cancer monitoring test.